Rapid Response: How Cost Plus Drugs is revolutionizing pharma, with CEO Alex Oshmyansky
Masters of Scale
Navigating Drug Pricing Challenges
This chapter explores the struggles of a new pharmaceutical company in securing partnerships with traditional manufacturers due to industry pressures. It highlights the case of albendazole to illustrate the potential for reduced drug costs and critiques the role of Pharmacy Benefit Managers in contributing to inflated prices.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
